NCT06411912View on ClinicalTrials.gov

A Study of NIDO-361 in Patients With SBMA

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Spinal and Bulbar Muscular AtrophyKennedy's Disease
Interventions
DRUG

NIDO-361

Tablets containing 100mg of NIDO-361 for oral administration.

DRUG

Placebo

Placebo oral tablets

Trial Locations (5)

Unknown

Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center, Copenhagen

IRCCS Istituto Neurologico Carlo Besta, Milan

Azienda Ospedale Università di Padova, Padua

Kyungpook National University Chilgok Hospital, Daegu

University of College London Hospital (UCLH), London

Sponsors
All Listed Sponsors
lead

Nido Biosciences, Inc.

INDUSTRY

NCT06411912 - A Study of NIDO-361 in Patients With SBMA | Biotech Hunter | Biotech Hunter